Your choices go into the PDF (cover and captions); this bar does not.
Rebalix
Comparison report · official data side by side

CD9 vs EHFC


CD9Amundi MSCI Europe High Dividend Factor UCITS ETF EUR Acc
LU1681041973 · Equity · Europe · Dividend
EHFCAmundi MSCI Europe High Dividend Factor UCITS ETF Dist
LU3402750635 · Equity · Europe · Dividend
Open the interactive comparison on rebalix.com →

Comparison window: · currency: 🇪🇺 EUR · inflation: 🇮🇹 Italy · distributions: reinvested where declared

Report produced on 10 September 2026 · data as of the dates shown per section
Sources: official issuer documents (KID, factsheet, declared NAV series and holdings), ESMA register, ECB rates, Eurostat
Public methodology: rebalix.com/en/methodology

Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.

RebalixCD9 vs EHFC · report of 10 September 2026

The funds at a glance

From official issuer documents and the ESMA register
CD9LU1681041973Amundi MSCI Europe High Dividend Factor UCITS ETF EUR AccEquity · Europe · Dividend
Declared index
MSCI Europe High Dividend Yield Net Return EUR Index
TER
0.23%
Transaction (KID)
0.00%
Fund size
496 mln EUR
Launch
30 Jan 2018
Currency
EUR
Replication
Synthetic (swap)
Hedging
No
Holdings
48
Distributions 12m
acc.
Effective 🇮🇹 rate
26.00%
EHFCLU3402750635Amundi MSCI Europe High Dividend Factor UCITS ETF DistEquity · Europe · Dividend
Declared index
MSCI Europe High Dividend Yield Net Return EUR Index
TER
0.23%
Transaction (KID)
0.00%
Fund size
1 mln EUR
Launch
2 Jul 2026
Currency
EUR
Replication
Synthetic (swap)
Hedging
No
Holdings
49
Distributions 12m
n/a
Effective 🇮🇹 rate
26.00%

Tracking difference — year by year

Fund minus index, from issuer-declared series (complete calendar years). Each measures adherence to its OWN index.
CD93y avg: +0.06%/anno
2025
+0.11%
2024
+0.02%
2023
+0.06%
2022
−0.02%
2021
+0.05%
2020
+0.23%
EHFCn/d
not honestly computable
Rebalix · CD9 vs EHFCsection 1 of 3
RebalixCD9 vs EHFC · report of 10 September 2026
CD9Amundi MSCI Europe High Dividend Factor UCITS ETF EUR Acc · LU1681041973 · Equity · Europe · Dividend
EHFCAmundi MSCI Europe High Dividend Factor UCITS ETF Dist · LU3402750635 · Equity · Europe · Dividend

Geographic composition

% of portfolio, from full declared holdings
CD9EHFCUnited States98.0%98.3%France0.6%0.6%

Sector composition

GICS sectors, same sources and dates
CD9EHFCInformation Technology50.2%45.0%Consumer Discretionary19.3%21.7%Health Care8.1%10.0%Industrials6.7%7.0%Communication Services5.7%9.2%Financials4.1%1.4%Materials3.3%2.9%Consumer Staples1.0%1.0%

Portfolio overlap

36 common holdings · ticker match on full official portfolios
25%50%75%100%Weight of common holdings in CD983.3%Weight of common holdings in EHFC86.3%Truly shared part (duplicated investment)81.4%
How the shared part is computed: for each security held by both funds, only the SMALLER of the two weights counts — a stock at 5% in one fund and 1% in the other overlaps by 1%, not 5%. Summed over all 36 common holdings this gives 81.4%: buying both funds, roughly this share of your money buys the same stocks twice. Matching uses the ISIN of each security, as published by both issuers in their baskets.
Rebalix · CD9 vs EHFCsection 2 of 3
RebalixCD9 vs EHFC · report of 10 September 2026

Full comparison table

"—" = not published by the source, never estimated
CD9Amundi MSCI Europe High Dividend Factor UCITS ETF EUR Acc · LU1681041973 · Equity · Europe · Dividend
EHFCAmundi MSCI Europe High Dividend Factor UCITS ETF Dist · LU3402750635 · Equity · Europe · Dividend
MetricCD9EHFCNote
Identity
CategoryEquity · Europe · DividendEquity · Europe · DividendRebalix engine classification
ReplicationSynthetic (swap)Synthetic (swap)as declared by the issuer
Currency hedgingNoNosource: class name, factsheet
Income policyaccumulatingdistributing
Costs
TER0.23%0.23%from the KID
Transaction costs (KID)0.00%0.00%internal
All-in cost0.23%0.23%TER + transaction
Tracking difference (3a)+0.06%vs its OWN index
Performance in euro (ECB rates)
1 year+17.4%
3 years+55.5%
5 years+76.2%
10 years— = series younger than the window
Risk · last 3 years
Volatility (ann.)+10.52%
Max drawdown−12.81%
Sharpe1.11risk-free = ECB MRO avg
Sortino1.53like Sharpe, downside only
Distributions (fund currency)
Frequencyaccumulating classhistory not available
Distributions, last 12 monthsaccumulating classhistory not availableper share
Distribution yieldaccumulating classhistory not available12 months / NAV
Last ex-dateaccumulating classhistory not available
Italian taxation
Effective capital-gains rate26.00%26.00%white list, current half-year
Documents & exchanges
Listing venues97ESMA register
Borsa Italiana ticker
Indicative cumulative cost: on 10,000 euro over 5 years (stated assumption: 5%/yr growth, cost = TER + transaction) ~146 euro CD9 · ~146 euro EHFC. Broker costs not included.

Disclaimer

This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.

Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.

Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.

Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.

Rebalix · CD9 vs EHFCsection 3 of 3